CTI (Computerized Thermal Imaging) gets FDA panel review date for thermal imager:
This article was originally published in Clinica
Executive Summary
The US FDA's radiological devices panel is scheduled to review on October 16 Computerized Thermal Imaging's (CTI) premarket approval application for its thermal breast imaging system. The BCS 2100 system, which is being assessed by the panel as an adjunct to mammography, uses thermal imaging technology to provide a physiological profile of the breast, rather than the anatomical profile provided by mammograms. The device could provide an accurate and non-invasive way of helping to distinguish between benign and malignant lesions, thereby preventing unnecessary surgical breast biopsies, says the Lake Oswego, Oregon firm, which already has approval to market the system in Europe.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.